Table 1.

Summary of efficacy endpoints in therapy-naive participants in phase III studies of dolutegravir.

	SPRING-2 (N = 822)	SINGLE (N = 833)	FLAMINGO (N = 484)
Treatment-related discontinuation = failure
DTG	386/411 (93%)	391/414 (94%)	238/242 (98%)
Comparator	379/411 (92%)	365/419 (87%)	233/242 (96%)
Difference (CIa)	1.2 (−2.6, 5.1)	7.7 (3.6, 11.7)	2.4 (−0.7, 5.4)
Efficacy-related discontinuation = failure
DTG	391/411 (94%)	396/414 (95%)	240/242 (99%)
Comparator	383/411 (93%)	402/419 (95%)	240/242 (99%)
Difference (CIa)	1.5 (−2.1, 5.1)	0.2 (−2.9, 3.3)	0.2 (−1.7, 2.1)

CI, confidence interval; DTG, dolutegravir.

^aDifference based on Kaplan–Meier estimates; CI based on Greenwood's formula.